Pandemic-generated demand behind strong sales of Flexion’s osteoarthritic drug

Flexion became the latest company to report an unexpected boost in sales during the COVID-19 pandemic with second quarter sales for osteoarthritis drug Zilretta that beat consensus estimates by over $5 million.

On Tuesday, Flexion Therapeutics Inc. (NASDAQ:FLXN) closed up 12% to $13.12 after reporting that Zilretta sustained-release triamcinolone acetonide brought in $15.4 million in 2Q20, beating consensus estimates of almost $10 million. ...